Swiss drugmaker Roche Holding said today it had agreed to buy CuraGen Corporation's life sciences subsidiary for up to $154.9 million.
Roche will pay 454 Life Sciences Corporation's shareholders $140 million in cash.
They may also receive a further $14.9 million in cash from holders of currently outstanding stock options and warrants, if these are exercised, Roche said in a statement.
Separately, Roche also said its Avastin drug had gained approval in the European Union for first-line treatment of metastatic breast cancer.
CuraGen said it would receive about $85 million before fees and expenses, presuming exercise of all outstanding stock options, of which $14 million will be held in escrow.
